

ORIGINAL

TSCA NON-CONFIDENTIAL BUSINESS INFORMATION

DOCUMENT DESCRIPTION	DOCUMENT CONTROL NUMBER	DATE RECEIVED
8EHQ-11-18438	88110000322	9/12/11

COMMENTS:

DOES NOT CONTAIN CBI



The Chemical Company

338118

Helping Make
Products Better™

September 7, 2011



RECEIVED
OPT CBIC
2011 SEP 12 AM 11:25

Via Federal Express

United States Environmental Protection Agency - East
Attn: TSCA Section 8(e)
Room 6428
1201 Constitution Avenue, NW
Washington, DC 20004

Subject: Notice in Accordance with Section 8(e): Results of a 5-Day Repeated Intravenous Injection Study with Hexamoll DINCH, IUPAC Name: 1,2-Cyclohexane dicarboxylic acid, di(isononyl)ester (CAS No. 47419-59-0)

Dear Section 8(e) Coordinator:

BASF Corporation is submitting results of a 5-Day Repeated Intravenous Injection Study with Hexamoll DINCH, IUPAC Name: 1,2-Cyclohexane dicarboxylic acid, di(isononyl)ester (CAS No. 47419-59-0) conducted by BASF SE, Ludwigshafen, Germany.

Control (Intralipid 20%) and test article (Intralipid 20% plus DINCH) were administered once daily for five consecutive days by intravenous infusion over 10 minutes. Daily average daily dose per low, mid, and high dose animals was 61.25, 105, and 268.75 mg/kg, respectively.

All animals survived and appeared normal throughout the study. No statistical differences for body weight at each time point by sex were observed between control and test article groups. Although there were a few statistical differences observed between control and test article groups for various hematology and clinical chemistry parameters, no toxicological trends were observed and the differences were not considered toxicologically or biologically significant. There were some statistical differences in organ weights between control and test groups.

At necropsy, petechiae in the lungs was prevalent in several Day 5 test article animals (all groups), but only observed in one Day 5 control article animal. The Day 5 necropsy observations were considered predominantly related to test article administration rather than the test substance itself. Only selected tissues were microscopically evaluated. Hemorrhage and vacuolated interstitial histiocytes in the lungs and cytoplasmic vacuolation involving the reticuloendothelial cells of the spleen and Kupffer cells of the liver were observed in rats administered the test article intravenously for 5 consecutive days; the incidence of these lesions was lower for the low and mid-dose groups, and after 5 days of recovery. These lesions are thought to reflect an elimination process of the hydrophobic test substance; indeed, these findings have been described by others following intravenous infusion of lipids into humans and experimental animals (Koga *et al.*, *Ann. Surg.* 181: 186-190, 1975; Stuart and Smith, *J. Pathol.* 115: 63-71, 1975; Penco *et al.*, *Nutrition* 10:26-31, 1994; Driscoll *et al.*, *Clin. Nutr.* 24: 105-113, 2005)

BASF Corporation
100 Campus Drive
Florham Park, NJ 07932
Tel (800) 526-1072
www.basf.com/usa



CONTAINS NO CBI



The Chemical Company

United States Environmental Protection Agency – East

September 7, 2011

Page 2

BASF Corporation understands that reporting of the results from this study under TSCA 8(e) is in accordance with EPA's policy.

If you have any questions, please contact the undersigned at (973) 245-6693.

Sincerely,

Janet Cerra

Janet Cerra
Product Regulatory Center of Expertise
North America

/

Hexamoll DINCH_082511 Letter.doc

From: (973) 245-6693
 Janet Cerra
 BASF
 100 Campus Drive

Origin ID: LKKA



J11201104290225

Florham Park, NJ 07932

Ship Date: 08SEP11
 ActWgt: 1.0 LB
 CAD: 4487533/INET3180

Delivery Address Bar Code



SHIP TO: (202) 564-8930

BILL SENDER

Attn: TSCA Section 8(e)

USEPA East

Room 6428

1201 Constitution Avenue, NW

Washington, DC 20004

Ref # US635018

Invoice #

PO #

Dept #

FRI - 09 SEP A1
 STANDARD OVERNIGHT

TRK# 7951 6202 3961



0201

ZD RDVA

20004

DC-US

DCA



50FG2/4299/F5F4

After printing this label.

1. Use the 'Print' button on this page to print your label to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

Warning: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number.

Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com. FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$500, e.g. jewelry, precious metals, negotiable instruments and other items listed in our Service Guide. Written claims must be filed within strict time limits, see current FedEx Service Guide.